Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

14.50
+1.6212.58%
Pre-market: 14.640.1400+0.97%09:28 EDT
Volume:12.43M
Turnover:174.91M
Market Cap:1.43B
PE:-2.49
High:14.58
Open:13.22
Low:13.20
Close:12.88
52wk High:39.89
52wk Low:12.73
Shares:98.32M
Float Shares:80.72M
Volume Ratio:2.64
T/O Rate:15.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-4.90
PE(LYR):-2.49

Loading ...

Ultragenyx EVP, Chief Legal Officer Karah Parschauer reports sale of 1,899 common shares worth $46,749.38

Reuters
·
Jun 16

Assessing Ultragenyx Pharmaceutical (RARE) Valuation After UX111 FDA Review Acceptance And Growing GTX-102 Optimism

Simply Wall St.
·
Jun 09

Does Rising GTX-102 Focus Recast Ultragenyx (RARE) as a Concentrated Angelman Syndrome Risk-Reward Story?

Simply Wall St.
·
Jun 07

Ultragenyx Pharmaceutical (RARE) Receives a Buy from J.P. Morgan

TIPRANKS
·
May 23

Ultragenyx grants 17,567 RSUs to 11 new hires under inducement plan

Reuters
·
May 23

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 23

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 23

Ultragenyx Pharma Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
May 21

Ultragenyx price target raised to $96 from $84 at Cantor Fitzgerald

TIPRANKS
·
May 21

Ultragenyx director Shehnaaz Suliman disposes 5,740 common shares for $144,228.8

Reuters
·
May 19

Ultragenyx shareholders approve amended 2023 incentive plan at annual meeting

Reuters
·
May 19

Ultragenyx price target lowered to $33 from $34 at Evercore ISI

TIPRANKS
·
May 12

Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (KOD), IN8bio (INAB) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
May 11

Ultragenyx Pharmaceutical (RARE) Valuation Check After Recent Share Price Momentum And Long Term Pressure

Simply Wall St.
·
May 11

Ultragenyx Pharma Is Maintained at Buy by Guggenheim

Dow Jones
·
May 08

Ultragenyx price target lowered to $43 from $52 at Guggenheim

TIPRANKS
·
May 08

Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference

GlobeNewswire
·
May 07

Stock Track | Ultragenyx Pharmaceutical Soars 5.32% Intraday on Positive Analyst Ratings

Stock Track
·
May 06

Ultragenyx Pharma Is Maintained at Neutral by Wedbush

Dow Jones
·
May 06

Wedbush Trims Price Target on Ultragenyx Pharmaceutical to $26 From $27, Maintains Neutral Rating

MT Newswires Live
·
May 06